In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

President Trump sent letters Thursday to 17 of the world’s largest drug companies, telling them to take more steps to slash ...

Hidradenitis suppurativa is associated with a higher risk for new-onset depression and anxiety, which may occur despite ...

A fresh ultimatum demanding "binding commitments" to lower U.S. drug prices sent pharma firms scrambling Friday.

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Perspective Therapeutics' pipeline led by VMT-a-NET shows early potential, but adoption risks remain despite solid cash ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Switzerland, home to some the world's most recognisable luxury brands, now faces an upcoming 39 per cent tariff from the US ...

In a market note on Wednesday, Scotiabank increased its price target for Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) stock ...